News > Page 48

• 

  Key Highlights from Ipsen S.A.'s Annual General Meeting 2024

  5/28/2024
• 

  Ipsen Outlines Future Strategies and Commitments at Annual General Meeting

  5/28/2024
• 

  Breakthrough in Hypercortisolism: Relacorilant's Promising Phase 3 Results

  5/28/2024
• 

  New Hope for Patients with Multiple Myeloma: FDA Prioritizes Isatuximab Combo

  5/28/2024
• 

  Promising New Insights into Hepatitis B Treatment at EASL™ 2024

  5/28/2024
• 

  New Treatment for High-Risk Early Triple-Negative Breast Cancer Shows Promising Results

  5/28/2024
• 

  Recent Advances in Treating Atrial Fibrillation: The Role of Diet and Technology

  5/28/2024
• 

  Altamira Therapeutics Enhances RNA Delivery Stability: Key Developments and Future Plans

  5/28/2024
• 

  New Hope for ADPKD Patients: Phase II Clinical Trials for Tamibarotene Underway

  5/28/2024
• 

  Promising New Therapy for a Rare Neurological Disorder Fast Tracked by FDA

  5/28/2024